ARCHIVES

Single-Agent Phase III Trial Comparing Vectibix to Erbitux Meets Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 36 No. 5 | May 31, 2013

Download PDF Visit The Full Archive

Related Articles

In Brief: Patent For Semisynthetic Taxol Issued To FL Scientist; Simone To Chair Pediatric Group

June 7, 1991

USC, Wisconsin Get Construction Grants Totaling $1.5 Million

March 23, 1990

NCI T BE More Flexible In Funding RFAs Above Paylines

June 23, 1989

Obituary: Joseph Burchenal, 93, A Leader In Cancer Drug Development at MSKCC.

March 17, 2006

Flood Mistrial

February 9, 1979

Cancer Groups Urge Support For Comprehensive Cancer Care Legislation.

June 29, 2007